Table of Contents Author Guidelines Submit a Manuscript
Case Reports in Medicine
Volume 2014, Article ID 964082, 5 pages
http://dx.doi.org/10.1155/2014/964082
Case Report

Bortezomib Induced Hepatitis B Reactivation

1Department of Internal Medicine, Providence Hospital and Medical Centers, 16001 W 9 Mile Road, Southfield, MI 48075, USA
2Division of Nephrology, Department of Medicine, Providence Hospital and Medical Centers, 16001 W 9 Mile Road, Southfield, MI 48075, USA
3Division of Hematology & Oncology, Department of Medicine, Providence Hospital and Medical Centers, 16001 W 9 Mile Road, Southfield, MI 48075, USA
4Division of Gastroenterology, Department of Medicine, Henry Ford Health System, Detroit, MI 48202, USA

Received 14 March 2014; Revised 12 April 2014; Accepted 13 April 2014; Published 4 May 2014

Academic Editor: Gianfranco D. Alpini

Copyright © 2014 Salwa Hussain et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. Centers for Disease Control and Prevention, “Hepatitis B FAQs for health professionals,” 2012, http://www.cdc.gov/hepatitis/HBV/HBVfaq.htm.
  2. J. H. Hoofnagle, “Reactivation of hepatitis B,” Hepatology, vol. 49, no. 5, pp. S156–S165, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. Y. H. Huang, H. C. Lin, and S. D. Lee, “Management of chemotherapy-induced hepatitis B virus reactivation,” Journal of the Chinese Medical Association, vol. 75, no. 8, pp. 359–362, 2012. View at Google Scholar
  4. NCI Drug Dictionary, “National Cancer Institute at the National Institutes of Health,” http://www.cancer.gov/drugdictionary.
  5. Y. Tong, J. Qian, Y. Li, H. Meng, and J. Jin, “The high incidence of varicella herpes zoster with the use of bortezomib in 10 patients,” American Journal of Hematology, vol. 82, no. 5, pp. 403–404, 2007. View at Publisher · View at Google Scholar · View at Scopus
  6. R. Goldberg, E. Smith, S. Bell et al., “Bortezomib monotherapy in patients with multiple myeloma is associated with reactivation of hepatitis B,” Internal Medicine Journal, vol. 43, no. 7, pp. 835–836, 2013. View at Publisher · View at Google Scholar
  7. H. Tanaka, I. Sakuma, S. Hashimoto et al., “Hepatitis B reactivation in a multiple myeloma patient with resolved hepatitis B infection during bortezomib therapy: case report,” Journal of Clinical and Experimental Hematopathology, vol. 52, no. 1, pp. 67–69, 2012. View at Publisher · View at Google Scholar
  8. S. Beysel, Z. A. Yeǧin, and M. Yaǧci, “Bortezomib-associated late hepatitis B reactivation in a case of multiple myeloma,” Turkish Journal of Gastroenterology, vol. 21, no. 2, pp. 197–198, 2010. View at Publisher · View at Google Scholar · View at Scopus
  9. S. F. Anna Lok and B. J. McMahon, “Chronic hepatitis B: update 2009,” Hepatology, vol. 50, no. 3, pp. 27–28, 2009. View at Google Scholar
  10. C. A. Naranjo, U. Busto, E. M. Sellers et al., “A method for estimating the probability of adverse drug reactions,” Clinical Pharmacology and Therapeutics, vol. 30, pp. 239–245, 1981. View at Google Scholar
  11. A. S. F. Lok, R. H. S. Liang, E. K. W. Chiu, K.-L. Wong, T.-K. Chan, and D. Todd, “Reactivation of hepatitis B virus replication in patients receiving cytotoxic therapy: report of a prospective study,” Gastroenterology, vol. 100, no. 1, pp. 182–188, 1991. View at Google Scholar · View at Scopus
  12. R. Loomba, A. Rowley, R. Wesley et al., “Systematic review: the effect of preventive lamivudine on hepatitis B reactivation during chemotherapy,” Annals of Internal Medicine, vol. 148, no. 7, pp. 519–528, 2008. View at Google Scholar · View at Scopus
  13. W. Yeo and P. J. Johnson, “Diagnosis, prevention and management of hepatitis B virus reactivation during anticancer therapy,” Hepatology, vol. 43, no. 2, pp. 209–220, 2006. View at Publisher · View at Google Scholar · View at Scopus
  14. Y. H. Huang, L. T. Hsiao, Y. C. Hong et al., “Randomized controlled trial of entecavir prophylaxis for rituximab-associated hepatitis B virus reactivation in patients with lymphoma and resolved hepatitis B,” Journal of Clinical Oncology, vol. 31, pp. 2765–2772, 2013. View at Publisher · View at Google Scholar
  15. D. H. T. Mya, S. T. Han, Y. C. Linn, W. Y. K. Hwang, Y. T. Goh, and D. C. L. Tan, “Risk of hepatitis B reactivation and the role of novel agents and stem-cell transplantation in multiple myeloma patients with hepatitis B virus (HBV) infection,” Annals of Oncology, vol. 23, no. 2, pp. 421–426, 2012. View at Publisher · View at Google Scholar · View at Scopus
  16. B. Blanco, J. A. Pérez-Simón, L. I. Sánchez-Abarca et al., “Bortezomib induces selective depletion of alloreactive T lymphocytes and decreases the production of Th1 cytokines,” Blood, vol. 107, no. 9, pp. 3575–3583, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. C. M. Weinbaum, I. Williams, E. E. Mast et al., “Recommendations for identification and public health management of persons with chronic hepatitis B virus infection,” MMWR Recommendations and Reports, vol. 57, pp. 1–20, 2008. View at Google Scholar